3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Gynecologic
2
Gastrointestinal
2
Dermatologic
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
2
Thyroid Cancer, Papillary
2
Thyroid Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma, Follicular
1
Interventions
selpercatinib
2
trametinib
1
ribociclib
1
repotrectinib
1
pralsetinib
1
lutetium Lu 177 dotatate
1
dabrafenib
1
copper dotatate CU-64
1
cobimetinib
1
alectinib
1
Vemurafenib
1
Sunitinib
1
Lutetium-177
1
Lutetium
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
cobimetinib
×
Endocrine
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled